The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
News|Articles|June 23, 2015
European Pharmacopoeia Commission Updates Ph.Eur.
Author(s)Pharmaceutical Technology Editors
The European Pharmacopoeia adopts six new texts and revises 31 monographs in its 152nd session.
Advertisement
The European Directorate for the Quality of Medicines & HeathCare (EDQM) announced that the European Pharmacopoeia Commission (Ph.Eur.) announced that the commission held its 152nd session in Strasbourg on June 16–17, 2015. The session resulted in six new texts, 31 revised monographs, and six revised general chapters.
The following were included in the updates:
- A new general monograph on chemical precursors for radiopharmaceutical preparations.
- A revised chapter on the use of the test for bacterial endotoxins, which includes new recommendations on the need to perform risk assessment when using the bacterial endotoxin test as a pyrogenicity test, due to the potential contamination by nonendotoxin pyrogens; and a section on how to set limits for bacterial endotoxins.
- A revision to the general chapter on potentiometric determination of pH.
- A revision to the general chapter on residual solvents to align the latter to the latest version of the ICH Q3C (R5).
- A revised version of the chapter on pyrogens, which recommends replacing this test by the Monocyte-activation test wherever possible and after product-specific validation to avoid the use of live animals.
The new texts become affective July 1, 2016 and will be published in Supplement 8.8 of the Ph.Eur.
Source:
Advertisement
Related to this article
Manish Baviskar, Hubot CDMO, on ALCOA++ data integrity, model version change control, continuous monitoring, and human sign-off.
The agreement between CDER and OII with allow for coordinated marketing application assessments and inspections.
Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
Sanjay Konagurthu, PhD, senior director of Science and Innovation at Thermo Fisher Scientific, explains what teams need to do to ensure the usefulness of AI and what strides have been made with AI in regulatory submissions.
Advertisement
Advertisement